Gilead, Kite short­en Yescar­ta man­u­fac­tur­ing by two days in 'in­cre­men­tal' im­prove­ment

Gilead and Kite an­nounced Tues­day it re­ceived FDA ap­proval to short­en its man­u­fac­tur­ing process for the cell ther­a­py Yescar­ta, a move ex­pect­ed to re­duce the time pa­tients need to wait for the treat­ment by two days.

The short­en­ing, mea­sured by what’s known as “me­di­an turn­around time (TAT),” will fall from 16 days to 14 days, Gilead es­ti­mates. David Porter, the di­rec­tor of cell ther­a­py and trans­plants at Penn Med­i­cine, told End­points News any im­prove­ment in me­di­an TAT is good, but Tues­day’s up­date rep­re­sents one that is “in­cre­men­tal.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER